ADVANCE infectious diseases pharmacy through collaboration, research and education and LEAD antimicrobial stewardship to OPTIMIZE the care of patients with infections in every practice setting

  • Home
  • Live CE Webinar: Breaking Bad Bacteria: Mastering the 2024 CLSI Antimicrobial Susceptibility Testing Updates

Live CE Webinar: Breaking Bad Bacteria: Mastering the 2024 CLSI Antimicrobial Susceptibility Testing Updates

  • 07 Aug 2024
  • 12:00 PM - 1:30 PM

Wednesday, August 7, 2024
12:00 pm – 1:30 pm CT / 1:00 pm – 2:30 pm ET

Cost: FREE for SIDP, ACCP ID PRN and CLSI Members! $15 for non-member attendees


  • SIDP members: No code needed. Login using your SIDP account to enroll at no cost.
  • ACCP ID PRN members: create an SIDP login then enter the code provided by your membership group in the Enrollment Key box to participate in this activity at no cost.
  • CLSI members: Enroll via CLSI. 

This annual webinar provides updates on the latest breakpoint recommendations from CLSI and offers practical strategies on incorporating those changes into clinical practice. Speakers will address the importance of partnerships between pharmacists and laboratory professionals on effective implementation of updates to enhance clinical practice. Audience polling will be included throughout, with an opportunity for Q&A at the end.

Target Audience:

This activity was planned to meet the educational needs of Pharmacists and Laboratory Professionals.

Learning Objectives:

  • Summarize highlights from the 2024 CLSI M100 standards for antimicrobial susceptibility testing and reporting.
  • Examine nuances that may be encountered when performing antimicrobial susceptibility testing (AST) for carbapenem-resistant bacteria.
  • Evaluate species-specific guidance for AST of Staphylococcus sp. and ceftriaxone dosing guidance for methicillin-susceptible Staphylococcus aureus.
  • Discuss the revised breakpoints, reporting, and treatment recommendations for Stenotrophomonas maltophilia.


Navaneeth Narayanan, PharmD, MPH, BCIDP
Clinical Associate Professor
Department of Pharmacy Practice and Administration
Rutgers University
Piscataway, NJ

Virginia M. Pierce, MD, FIDSA
Clinical Associate Professor of Pathology and Pediatrics (Pediatric Infectious Diseases)
University of Michigan Medical School
Ann Arbor, MI



This activity is jointly provided by the Society of Infectious Diseases Pharmacists (SIDP) and the American College of Clinical Pharmacy Infectious Diseases Practice and Research Network (ACCP ID PRN). SIDP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0672-0000-24-013-L01-P
CPE credit: 1.5 contact hour (0.15 CEU)
Type of activity: Application
Activity Fee: SIDP, CLSI and ACCP ID PRN Member: Free / Non-Member: $15

To receive CE credit, participants must attend the webinar, then complete a self-assessment and activity evaluation online. Proof of completion will be submitted to NABP CPE Monitor.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Participants are responsible for verifying credits were transferred successfully to your NABP eProfile account before the ACPE 60-day deadline. After the 60 day deadline, SIDP will no longer be able to report your credit(s) for this activity.


Clinical and Laboratory Standards Institute is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.(R) Program.


This activity is self-funded by SIDP, CLSI, and members of ACCP ID PRN.


In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, SIDP asks all individuals involved in the development and presentation of CE activities to disclose all financial relationships with ineligible companies. All relevant financial relationships have been mitigated prior to the CE activity. The following financial relationships have been disclosed:

  • Dr. Narayanan (faculty): Research funding from Merck and Shionogi; Consultant, Advisor, Speaker for Astellas, Paratek, Beckman Coulter, and T2 Biosystems.
  • Dr. Pierce (faculty) has no financial relationship with an ineligible company to disclose.
  • SIDP planners, staff and other individuals who are in a position to control the content of this CE activity have no relevant financial relationships with an ineligible company to disclose.


Faculty members are asked to disclose when any unlabeled/investigational use of pharmaceuticals and devices is being discussed. This activity is intended for educational purposes and should not be used as a substitute for care or advice from a professional. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SIDP.

The planners and faculty of this continuing education activity have made all reasonable efforts to ensure the accuracy of the information presented in accordance with the latest available scientific knowledge at the time of publication. Healthcare professionals should verify all information and data with recommendations of other authorities before treating patients or employing any therapies described in this continuing education activity.


Society of Infectious Diseases Pharmacists •  PO Box 1488, Warrenville, IL 60555
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software